Sector Update: Health Care Stocks Rise Pre-Bell Thursday

MT NewswiresNov 21 09:13 ET

Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe

MT NewswiresNov 20 17:45 ET

Nurix Therapeutics Receives PRIME Designation From the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

GlobeNewswireNov 20 16:00 ET

Express News | Nurix Therapeutics Receives Prime Designation From the European Medicines Agency for Nx-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

ReutersNov 20 16:00 ET

Express News | Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024

ReutersNov 17 10:30 ET

Nurix Therapeutics Down Over 10%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow JonesNov 15 13:52 ET